Circulating antibodies to conjugated tryptophan derivatives of the IDO pathway in amyotrophic lateral sclerosis, Alzheimer's, Parkinson's and multiple sclerosis patients

Immuno-Analyse et Biologie Specialisee

Volumn 23, Issue 1, 2008, Pages 27-34

  Duleu, S ^a   Mangas, A ^a   Poulletier de Gannes, F ^b   Tranchant, M C ^c   Geffard, M ^a,b  

^a Gemacbio SA   (France)

^b UNIVERSITÉ BORDEAUX 1   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Multiple sclerosis; Parkinson's disease; Tryptophan derivatives

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; QUINOLINIC ACID; TRYPTOPHAN DERIVATIVE;

ADULT; AGED; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MULTIPLE SCLEROSIS; PARKINSON DISEASE; PRIORITY JOURNAL; UPREGULATION;

EID: 40849086198     PISSN: 09232532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immbio.2007.11.001     Document Type: Article

References (41)

1. Kwidzinski E., Bunse J., Kovac A.D., Ullrich O., Zipp F., Nitsch R., et al. IDO (indolamine 2,3-dioxygenase) expression and function in the CNS. Adv Exp Med Biol 527 (2003) 113-118
2. Robinson C.M., Hale P.T., and Carlin J.M. The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res 25 1 (2005) 20-30
3. Hwang S.L., Chung N.P., Chan J.K., and Lin C.L. Indoleamine 2, 3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokines. Cell Res 15 3 (2005) 167-175
4. Alberati-Giani D., Ricciardi-Castagnoli P., Köhler C., and Cesura A.M. Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells. J Neurochem 66 3 (1996) 996-1004
5. Liebau C., Baltzer A.W., Schmidt S., Roesel C., Karreman C., Prisack J.B., et al. Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma. Anticancer Res 22 (2002) 931-936
6. Lestage J., Verrier D., Palin K., and Dantzer R. The enzyme indoleamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen. Brain Behav Immun 16 5 (2002) 596-601
7. Fujigaki S., Saito K., Sekikawa K., Tone S., Takikawa O., Fujii H., et al. Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur J Immunol 31 8 (2001) 2313-2318
8. Guillemin G.J., Meininger V., and Brew B.J. Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis. Neurodegeneration 2 3-4 (2005) 166-176
9. Mnaimneh S., Geffard M., Veyret B., and Vincendeau P. Albumin nitrosylated by activated macrophages possesses antiparasitic effects neutralized by anti-NO-acetylated-cysteine antibodies. J Immunol 158 1 (1997) 308-314 1
10. Geffard M., Dulluc J., and Rock A.M. Antisera against the indolealkylamines: tryptophan, 5-hydroxytryptophan, 5-hydroxytryptamine, 5-methoxytryptophan, and 5-methoxytryptamine tested by an enzyme-linked immunosorbent assay method. J Neurochem 44 (1985) 1221-1228
11. Geffard M., Bodet D., Claudepierre P., Metzger J.M., and Sibillia J. Anticorps sériques circulants dirigés contre des antigènes modifiés par le NO dans les affections neurologiques et rhumatismales. Immunoanal Biol Spec 3 (1998) 209-217
12. Geffard M., Bodet D., Martinet Y., and Dabadie M.P. Detection of the specific IgM and IgA circulating in sera of multiple sclerosis patients: interest and perspectives. Immunoanal Biol Spec 17 (2002) 302-310
13. Duleu S., Van Der Velden C., Poulletier De Gannes F., Tranchant M.C., and Geffard M. Circulating antibodies to NO- and ONOO- modified antigens in amyotrophic lateral sclerosis, Alzheimer's disease and multiple sclerosis. Immunoanal Biol Spec 22 (2007) 273-281
14. Newhouse P., Tatro A., Naylor M., Quealey K., and Delgado P. Alzheimer's disease, serotonin systems, and tryptophan depletion. Am J Geriatr Psychiatry 10 (2002) 483-484
15. Guillemin G.J., Williams K.R., Smith D.G., Smythe G.A., Croitoru-Lamoury J., and Brew B.J. Quinolinic acid in the pathogenesis of Alzheimer's disease. Adv Exp Med Biol 527 (2003) 167-176
16. Widner B., Leblhuber F., Walli J., Tilz G.P., Demel U., and Fuchs D. Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm 107 3 (2002) 343-353
17. Widner B., Leblhuber F., and Fuchs D. Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. J Neural Transm 109 2 (2002) 181-189
18. Stone T.W., Mackay G.M., Forrest C.M., Clark C.J., and Darlington L.G. Tryptophan metabolites and brain disorders. Clinical Chem Lab Med 41 7 (2003) 852-859
19. Hansson O., Petersén A., Leist M., Nicotera P., Castilho R.F., and Brundin P. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad Sci USA 96 15 (1999) 8727-8732 20
20. Guillemin G., Croitoru-Lamoury J., Dormont J., Armati G., and Brew B.J. Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes. Glia 41 (2002) 371-381
21. Chiarugi A., Calvani M., Meli E., Traggiai E., and Moroni F. Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. J Neuroimmunol 120 1-2 (2001) 190-198
22. Qin Z.H., Chen R.W., Wang Y., Nakai M., Chuang D.M., and Chase T.N. Nuclear factor kappaB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum. J Neurosci 19 10 (1999) 4023-4033
23. Stastny F., Lisy V., Mares V., Lisa V., Balcar V.J., and Santamaria A. Quinolinic acid induces NMDA receptor-mediated lipid peroxidation in rat brain microvessels. Redox Rep 9 (2004) 229-233
24. Puntel R.L., Nogueira C.W., and Rocha J.B. N-methyl-d-aspartate receptors are involved in the quinolinic acid, but not in the malonate pro-oxidative activity in vitro. Neurochem Res 30 3 (2005) 417-424
25. Santamaria A., Galvan-Arzate S., Lisy V., Ali S.F., Duhart H.M., Osorio-Rico L., et al. Quinolinic acid induces oxidative stress in rat brain synaptosomes. Neuroreport 12 4 (2001) 871-874 26
26. Forrest C.M., Mackay G.M., Stoy N., Egerton M., Christofides J., Stone T.W., et al. Tryptophan loading induces oxidative stress. Free Radic Res 38 11 (2004) 1167-1171
27. Alberati-Giani D., Malherbe P., Ricciardi-Castagnoli P., Köhler C., Denis-Donini S., and Cesura A.M. Differential regulation of indoleamine 2,3-dioxygenase expression by nitric oxide and inflammatory mediators in IFN-gamma-activated murine macrophages and microglial cells. J Immunol 159 1 (1997) 419-426 1
28. Melillo G., Cox G.W., Biragyn A., Sheffler L.A., and Varesio L. Regulation of nitric-oxide synthase mRNA expression by interferon-gamma and picolinic acid. J Biol Chem 269 11 (1994) 8128-8133 18
29. Bosco M.C., Rapisarda A., Massazza S., Melillo G., Young H., and Varesio L. The tryptophan catabolite picolinic acid selectively induces the chemokines macrophage inflammatory protein-1 alpha and -1 beta in macrophages. J Immunol 164 6 (2000) 3283-3291 15
30. Malina H.Z., Richter C., Mehl M., and Hess O.M. Pathological apoptosis by xanthurenic acid, a tryptophan metabolite: activation of cell caspases but not cytoskeleton breakdown. BMC Physiol 1 1 (2001) 7
31. Bertel O., Malessa S., Sluga E., and Hornykiewicz O. Amyotrophic lateral sclerosis: changes of noradrenergic and serotonergic transmitter systems in the spinal cord. Brain Res 566 1-2 (1991) 54-60 6
32. Ogawa T., Matson W.R., Beal M.F., Myers R.H., Bird E.D., Milbury P., et al. Kynurenine pathway abnormalities in Parkinson's disease. Neurology 42 9 (1992) 1702-1706
33. Kwidzinski E., Bunse J., Aktas O., Richter D., Mutlu L., Zipp F., et al. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J 19 10 (2005) 1347-1349
34. Jhamandas K., Boegman R.J., Beninger R.J., and Bialik M. Quinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolites. Brain Res 529 1-2 (1990) 185-191
35. Alberati-Giani D., and Cesura A.M. Expression of the kynurenine enzymes in macrophages and microglial cells: regulation by immune modulators. Amino Acids 14 1-3 (1998) 251-255
36. Guidetti P., and Schwarcz R. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur J Neurosci 11 11 (1999) 3857-3863
37. Guillemin G.J., and Brew B.J. Implications of the kynurenine pathway and quinolinic acid in Alzheimer's. Redox Rep 7 4 (2003) 199-206
38. Holmes E.W. Expression and regulation of interferon-gamma-induced tryptophan catabolism in cultured skin fibroblasts. J Interferon Cytokine Res 18 7 (1998) 509-520
39. Rios C., and Santamaria A. Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem Res 16 10 (1991) 1139-1143
40. Samelson-Jones B.J., and Yeh S.R. Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry 45 28 (2006) 8527-8538 18
41. Wichers M.C., and Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. Psychiatry Neurosci 29 1 (2004) 11-17